Organic Active Ingredients TRIZ Cases

Propellant-based apomorphine compositions enable rapid buccal absorption while preventing oxidation and eliminating first-pass metabolism.

A pharmaceutical formulation uses benzyl alcohol as a preservative to suspend ibrutinib particles in water.

Segmented antisense oligonucleotides with liposome delivery resolve the specificity-reliability trade-off in PAR4 natural antisense transcript targeting.

Flavylium excipients mediate tetrahydrocannabinol partitioning into gastrointestinal epithelium via non-covalent interactions.

Specific beta-glucan molecular weights activate Dectin-1 receptors to boost lactic acid bacterium populations and regulatory T-cell numbers.

Fluorinated glucosylceramide synthase inhibitors overcome poor brain distribution of prior drugs, enabling effective treatment for Gaucher and Fabry diseases.

Hyaluronic acid protects xylometazoline from hydrolysis and restores mucociliary activity while reducing toxicity.

Fructose 1,6-bisphosphate resolves low melanin production from essential oils by stimulating synthesis in melanocytes.

Amorphous drug formulations via hot melt extrusion using organic solvents to lower processing temperatures.

Indole derivatives inhibit MKLP2 pathways to reduce endometriosis lesion volume, addressing limited single-molecule treatment options.

Biodegradable polymer sutures encapsulate therapeutic agents to provide sustained drug release, preventing post-operative infection and inflammation.

Specific casein hydrolysate peptides increase plasma adiponectin to improve insulin sensitivity and manage weight.

Structural parameter changes create receptor degraders that prevent treatment resistance while reducing side effects on healthy tissues.

Beta-glucan nanoparticles adhere to gastric mucus to deliver siRNA and chemotherapy drugs locally.

Solid dispersion technology transforms unstable crystalline c-KIT inhibitors into stable amorphous states, resolving formulation purity challenges.

Galacto-rhamnogalacturonate polysaccharides bind galectin-3, reducing fibrosis and edema while improving pulmonary function.

A convergent SNAr coupling process assembles acyclic HCV protease inhibitors from modular peptidic and quinoline fragments.

In situ administration of nonreplicating virus-like particles modifies the tumor microenvironment to induce systemic anti-tumor immunity.

Anti-gelling agents prevent gel formation in high-concentration formulations, maintaining bioavailability and reducing degradation products.

Combining a CXCR2 agonist with a CXCR4 antagonist mobilizes hematopoietic stem cells from bone marrow into peripheral blood.

Lactose-free naltrexone dispersible tablets eliminate adverse symptoms in Crohn's disease patients while maintaining high stability and dissolution rates.

Direct coating of neutral cores with specific omeprazole-to-binder ratios increases drug loading while reducing granule size distribution issues.

Cutibacterium avidum GENSC01 strain produces bacteriocin to inhibit Staphylococcus aureus growth and biofilm formation.

Macrocyclic sulfondiimine compounds overcome low potency at high ATP concentrations by using a biaromatic ring to extend target residence time.

Steviol glycosides replace glucose to prevent peritoneal membrane damage and systemic side effects during chronic renal failure treatment.

Exosomes encapsulated in hydrogel stimulate dental pulp stem cell migration and differentiation for tissue repair.

Combining limonoids with SGLT-2 inhibitors reduces required doses, minimizing urinary tract infections and hypoglycemia.

Small molecule mitofusin modulating agents restore mitochondrial elongation, trafficking, and fusion to correct defects in neurons with mitochondrial mutations.

A pH regulating agent in an orally disintegrating nicotine tablet alters ionization states to enable rapid buccal absorption while preventing throat irritation.

Targeted compounds bind the ubiquitin E2 variant domain, disrupting essential protein interactions to inhibit viral release and replication.

Transduced neural cells continuously produce enzymes in cerebrospinal fluid, bypassing blood-brain barrier limits and reducing invasive injection risks.

A swallowable capsule deploys tissue-penetrating members to inject therapeutic agents directly into the intestinal wall.

Batroxobin shields bone marrow and heart tissue from drug-induced harm, enabling higher anticancer dosages.

Isoindolinone compounds modulate MRGPR X4 to treat chronic itch conditions.

A nucleic acid transfecting composition combines cationic lipids with phospholipids to facilitate effective cellular delivery.

Ultrasonic vibration segments a polymer stream into controlled droplets, resolving size variability and scalability limits of bulk sonication.

Overexpressing miR-137 via a pharmaceutical composition reduces nicotine preference and withdrawal symptoms, addressing limitations of current therapies.

Thiazole compounds antagonize orexin receptors, resolving the lack of effective treatments for insomnia and psychiatric conditions.

Polyvinyl alcohol forms a solid dispersion with enzalutamide to maintain supersaturation, resolving pH-dependent solubility instability.

Formula I compounds inhibit PRMT5 enzyme activity to reverse gamma-globin silencing in hemoglobinopathies.

Specific R-group substitutions on the pyrazolo[1,5-a]pyrimidine core reduce in vivo toxicity while maintaining antiviral efficacy against RNA viruses.

A contact lens moisturizing composition uses a three-dimensional crosslinked structure to retain moisture independently of tear secretion.

A 11β-HSD2 inhibitor promotes potassium ion secretion into the colonic lumen.

A non-mechanical process precipitates digoxin from organic solvent to yield uniform 20-30 micrometer particles.

SOD mediates SAM transport across the blood-brain barrier to reduce amyloid-beta production.

Converts green tobacco nicotine to sulfate, adjusts pH to free base, and extracts with organic solvent to reduce hazardous waste.

RNAi compositions target exon 10 of the MAPT gene to inhibit 4R-tau transcript expression, addressing underlying disease pathology.

Proteolytic enzymes and sulfhydryl compounds increase chondroitin sulphate intestinal absorption, resolving low uptake limits in osteoarthritis treatment.

A p-toluenesulfonate salt formulation enhances bioavailability and tumor inhibitory activity.

Benzamil targets epithelial sodium channels to reduce thickened psoriatic plaques and improve skin condition.

Aza-heterocyclylmethyl substituents on thienouracil cores enhance receptor selectivity, addressing the lack of effective antagonists for pulmonary fibrosis.

A tablet composition uses cinacalcet hydrochloride with D90 ≤ 30 µm to enhance dissolution profile.

IgG3 beta-1 adrenergic receptor antibodies stabilize receptors to mitigate cardiac remodeling and failure.

Dynamic valve control maintains consistent airflow profiles despite variable user inhalation strength, ensuring reliable medication delivery.

Nucleic acid aptamers bind the TLR-4 extracellular domain to inhibit receptor activation and reduce tissue damage.

Triblock bottlebrush copolymers undergo sol-gel transition at physiological temperature to provide controlled release of therapeutic agents.

Acyl sulfonamide compounds inhibit KAT6A and KAT6B without genotoxic risk, expanding therapeutic options for cancer treatment.

Arylthiazine compounds scavenge lipid hydroperoxides to prevent cellular degeneration in age-related diseases like Alzheimer's.

A polymeric kernel and skin structure controls drug release through defined pores.

Novel 10-oxo-6,10-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine derivatives inhibit hepatitis B surface antigen activity.

Formamidino protection prevents palladium catalyst poisoning by free amines, enabling scalable synthesis of pure crystalline triazine derivatives.

An oily suspension stabilizes microparticles below 20 µm to prevent coagulation and reduce fecal excretion of hardly water-soluble drugs.

BNT411 modifies imidazoquinoline structures to activate TLR7 signaling, resolving dose-limiting toxicities from systemic administration.

Reducing binder to 0.9% w/w resolves the contradiction between tablet mechanical strength and dissolution profile.

Isoquinolone derivatives resolve kinase selectivity issues by targeting the BTK active site to treat autoimmune disorders.

Segmented genetic screening of ABCC2 polymorphisms predicts QT prolongation risk, enabling safer medication dosing and alternative compound selection.

A semi-solid lipid gel formulation provides sustained drug release through a homogenous suspension of active ingredients in glycerides.

Novel bifunctional compounds degrade SMARCA2 by recruiting it to a VHL E3 ubiquitin ligase, resolving specificity challenges in SMARCA4-deficient cancers.

Intravenous magnesium chloride and colchicine composition addresses refractory disc pain by reducing inflammation and myospasms without surgical intervention.

Acetylated saponin from Gypsophila elegans doubles transfection efficiency of SO1861 by forming nanoplexes with nucleic acids, peptides, and proteins.

Estetrol relaxes vascular constriction in the arteria uterina, increasing blood flow to treat hypertensive disorders of pregnancy and fetal growth retardation.

Optimized chemical structures inhibit Factor XIa and plasma kallikrein, reducing thrombotic effects without excessive bleeding risks.

Applying resistance inhibitory concentration metrics to target heteroresistant bacterial subpopulations and prevent drug resistance emergence.

Synthesized pyrimidine derivatives normalize liver functions and reduce degenerative changes in cells.

Topical ophthalmic compositions use penetrating peptides to transport siRNA across the cornea for targeted retinal ganglion cell protection.

Glycerol addition stabilizes hyaluronic acid solutions against sterilization degradation while reducing infection risks.

A modified hyaluronic acid composition delivers sustained joint lubrication and pain relief through a single injection formulation.

A quinazoline compound crosses the blood-brain barrier for oral brain tumor treatment.

Tetrahydroisoquinoline PRMT5 inhibitors block methyltransferase activity, reversing gamma-globin gene silencing and upregulating expression in cancer therapies.

mTOR inhibitors target hemangioma stem cells to reduce vasculogenic potential, addressing adverse effects from corticosteroids.

Multi-target receptor blockade in heterocyclic piperidine compounds prevents first-dose hypotension while maintaining effective blood pressure control.

Oral decitabine combined with tetrahydrouridine sustains therapeutic levels through cytidine deaminase inhibition.

Soluble thrombomodulin sequesters oxaliplatin in blood, preventing neurotoxicity while preserving tumor efficacy.

A transdermal delivery device containing dexmedetomidine and an acrylate adhesive with pendant hydroxyl groups passively releases the drug through the skin.

A synergistic blend of Konjac glucomannan and Xanthan gum forms a thixotropic complex that maintains API suspension in oral pharmaceutical formulations.

A viral receptor combines sialic acid compounds with a lipid spacer to enhance virus-binding affinity.

Oligopeptides bind directly to Notch ligand Jagged1 to block Jag1-Notch1 interactions, reducing gastrointestinal toxicity from non-specific inhibitors.

Segmented resin particles with cellulose acetate coatings maintain therapeutic plasma levels for 6 to 24 hours, reducing side effects from peak concentrations.

Selective AT2 receptor antagonists treat neuropathic pain and osteoporosis without the severe side effects of current therapies.

Chimeric CD154 polypeptides stabilize the ligand against proteolytic cleavage, resolving transient stability issues in refractory cancer treatment.